Form 4: Annexon Director Bettina Cockroft Granted 55,000 Stock Options

Annexon, Inc. Director Bettina M. Cockroft has been granted 55,000 stock options with an exercise price of $2.55, vesting over the next year, as reported in a recent SEC Form 4 filing.

Summary

• Bettina M. Cockroft, a Director of Annexon, Inc. (ANNX), acquired 55,000 stock options.
• The options have an exercise price of $2.55 per share.
• The transaction date for the option grant was June 5, 2025.
• The options are exercisable as to 100% of the total number of shares on the earlier of (i) the first anniversary of June 5, 2025, or (ii) the next Annual Meeting following June 5, 2025.
• Vesting is contingent upon Ms. Cockroft's continuous service as a director until the vesting date.
• The options have an expiration date of June 5, 2035.
• Following this transaction, Ms. Cockroft beneficially owns 55,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the option grant aligns the director's interests with shareholders and is a standard compensation practice, indicating stable corporate governance. It's not highly positive as it's a routine event and doesn't signal new strategic developments or immediate financial gains.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of compensation for directors, indicating normal corporate governance practices.

Negatives

• The options do not represent immediate share ownership or cash flow for the director; their value is contingent on the future stock price exceeding the exercise price.
• The value of the options is subject to market fluctuations and the company's performance.

Risks

• The stock options may not become 'in-the-money' if Annexon's common stock price does not rise above the $2.55 exercise price, rendering them worthless.
• The options are subject to forfeiture if the reporting person's continuous service as a director ceases before the vesting date.

Future Outlook

The future outlook indicates that the director's compensation is tied to the company's long-term performance, as the options vest over the next year and have a ten-year expiration period, incentivizing sustained engagement and value creation.

Industry Context

The granting of stock options to directors is a common practice across various industries, particularly in biotechnology and pharmaceutical sectors like Annexon, Inc., to attract and retain experienced board members and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice in the biotechnology and pharmaceutical industries, comparable to compensation structures seen at companies like Biogen Inc. or Gilead Sciences, Inc., which often include equity components to incentivize long-term performance.
• The vesting schedule, tied to continued service and an annual meeting, is typical for director equity grants, ensuring commitment to the company's governance and strategic direction.

Related Party Transactions

• The grant of stock options to Bettina M. Cockroft, a director of Annexon, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's incentives with shareholder interests, potentially leading to better long-term performance and value creation.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The stock options will vest on the earlier of the first anniversary of June 5, 2025, or the next Annual Meeting following June 5, 2025, subject to the director's continuous service.
• Upon vesting, the director will have the right to exercise the options and purchase common stock at the specified exercise price.

Key Dates

Keywords

Annexon, ANNX, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Beneficial Ownership, Equity Compensation, Corporate Governance